Unresectable Biliary Tract Cancer
3
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Systemic Chemotherapy Combined With Immunotherapy
Research Leaders
15 sponsors active, led by Shanghai Zhongshan Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer
Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study
Salvage mFOLFOX in BTC After Failure of Gemcitabine
Research Network
Common Treatments
- Systemic Chemotherapy Combined With Immunotherapy1
- 5fluorouracil Leucovorin Oxaliplatin1
- Nabpaclitaxel In Combination With Gemcitabine Cisplatin1
Active Sponsors
- Shanghai Zhongshan Hospital1
- Yunnan Cancer Hospital1
- Dong-A University Hospital1
- AHS Cancer Control Alberta1
- Zhejiang Cancer Hospital1
Top Investigators
Alberta Health services
Chung-Ang University Yongsan Hospital
Zhongda hospital, Southeast university, Nanjing, China
Related Conditions
- Dynamic Prediction Model1
- Immunotherapy1